Gastric cancer management: Kinases as a target therapy

Summary The molecular diagnostics revolution has reshaped the practice of oncology by facilitating the identification of genetic, epigenetic and proteomic modifications correlated with cancer, thus delineating ‘oncomaps’ for various cancer types. These advances have enhanced our understanding of gas...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental pharmacology & physiology 2017-06, Vol.44 (6), p.613-622
Main Authors: Farran, Batoul, Müller, Susanne, Montenegro, Raquel C
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
c-Met protein
Cancer
Clinical trials
Clinical Trials as Topic
Epidermal growth factor
Epidermal growth factor receptors
ErbB-2 protein
Gastric cancer
Growth factors
Humans
Inhibitors
Kinases
Molecular Targeted Therapy - methods
Monoclonal antibodies
precision medicine
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Protein Kinases - metabolism
Receptors
small‐molecule kinase inhibitors
Stomach Neoplasms - drug therapy
Stomach Neoplasms - enzymology
Stomach Neoplasms - pathology
Targeted cancer therapy
targeted therapy
TOR protein
Trastuzumab
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The molecular diagnostics revolution has reshaped the practice of oncology by facilitating the identification of genetic, epigenetic and proteomic modifications correlated with cancer, thus delineating ‘oncomaps’ for various cancer types. These advances have enhanced our understanding of gastric cancer, one of the most fatal diseases worldwide, and culminated in the approval of novel molecular therapies such as trastuzumab. Gastric tumours display recurrent aberrations in key kinase oncogenes such as Her2, epidermal growth factor receptor (EGFR), PI3K, mTOR or c‐Met, suggesting that these receptors are amenable to inhibition using specific drug agents. In this review, we examine the mutational landscape of gastric cancer, the use of kinase inhibitors as targeted therapies in gastric tumours and the clinical trials underway for novel inhibitors, highlighting successes, failures and future directions.
ISSN:0305-1870
1440-1681
DOI:10.1111/1440-1681.12743